MX2012007671A - Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea. - Google Patents

Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea.

Info

Publication number
MX2012007671A
MX2012007671A MX2012007671A MX2012007671A MX2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A MX 2012007671 A MX2012007671 A MX 2012007671A
Authority
MX
Mexico
Prior art keywords
corneal endothelial
endothelial cells
compound
therapeutic agent
agent
Prior art date
Application number
MX2012007671A
Other languages
English (en)
Spanish (es)
Inventor
Yuji Sakamoto
Tetsuo Kida
Hiroaki Takahashi
Takeshi Tarui
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2012007671A publication Critical patent/MX2012007671A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • C12N5/0621Eye cells, e.g. cornea, iris pigmented cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2012007671A 2009-12-29 2010-12-28 Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea. MX2012007671A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009299180 2009-12-29
PCT/JP2010/071424 WO2011080984A1 (en) 2009-12-29 2010-11-24 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
PCT/JP2010/073904 WO2011081221A1 (en) 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction

Publications (1)

Publication Number Publication Date
MX2012007671A true MX2012007671A (es) 2012-08-23

Family

ID=43598277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007671A MX2012007671A (es) 2009-12-29 2010-12-28 Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea.

Country Status (10)

Country Link
US (1) US20120288482A1 (enExample)
EP (1) EP2519237A1 (enExample)
JP (2) JP5750444B2 (enExample)
KR (1) KR20120099147A (enExample)
CN (1) CN102770136A (enExample)
BR (1) BR112012016128A8 (enExample)
CA (1) CA2785851A1 (enExample)
MX (1) MX2012007671A (enExample)
RU (1) RU2563141C2 (enExample)
WO (2) WO2011080984A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2788472T1 (sl) 2011-12-06 2019-04-30 Astellas Institute For Regenerative Medicine Način usmerjene diferencijacije, produciranja endotelijskih celic roženice
ES2763433T3 (es) 2013-11-27 2020-05-28 Kyoto Prefectural Public Univ Corp Aplicación de laminina a cultivos de células endoteliales de la córnea
US10959997B2 (en) 2013-12-27 2021-03-30 Kyoto Prefectural Public University Corporation Combined agent for cell therapy of corneal endothelial cell
US10034885B2 (en) 2014-09-24 2018-07-31 Kowa Company, Ltd. Corneal thickness modulating agent
US11633477B2 (en) * 2014-10-31 2023-04-25 Kyoto Prefectural Public University Corporation Treatment of cornea using laminin
EP3213761B1 (en) 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
US20190083543A1 (en) * 2016-02-15 2019-03-21 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
CN101310771B (zh) 2001-04-11 2012-08-08 千寿制药株式会社 视觉功能障碍改善剂
JP2004024852A (ja) 2002-04-30 2004-01-29 Amniotec:Kk 角膜内皮様シート、及びその作製方法
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005118582A1 (ja) * 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
EP1829876A4 (en) * 2004-11-26 2009-04-01 Asahi Kasei Pharma Corp NITROGENIC TRICYCLIC COMPOUND
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
EP1864664A4 (en) * 2005-03-10 2009-02-18 Mitsubishi Tanabe Pharma Corp PHARMACEUTICAL PREPARATION
WO2007083685A1 (ja) * 2006-01-19 2007-07-26 Senju Pharmaceutical Co., Ltd. 生体内で細胞増殖可能な角膜内皮製剤
CN101495117B (zh) * 2006-07-31 2012-08-15 千寿制药株式会社 含酰胺化合物的水性液体制剂
BRPI0816182A2 (pt) 2007-08-29 2015-04-14 Senju Pharma Co Agente para promoção de adesão celular endotelial corneana
JP5251632B2 (ja) 2008-05-13 2013-07-31 新日鐵住金株式会社 耐遅れ破壊特性に優れた高強度鋼材、高強度ボルト及びその製造方法
JP2010071424A (ja) 2008-09-19 2010-04-02 Toyota Motor Corp 変速機の制御装置

Also Published As

Publication number Publication date
WO2011080984A1 (en) 2011-07-07
JP2015155460A (ja) 2015-08-27
US20120288482A1 (en) 2012-11-15
BR112012016128A8 (pt) 2017-12-05
RU2012132443A (ru) 2014-02-10
RU2563141C2 (ru) 2015-09-20
KR20120099147A (ko) 2012-09-06
BR112012016128A2 (pt) 2016-05-31
EP2519237A1 (en) 2012-11-07
CA2785851A1 (en) 2011-07-07
CN102770136A (zh) 2012-11-07
WO2011081221A1 (en) 2011-07-07
JP2013515676A (ja) 2013-05-09
JP5750444B2 (ja) 2015-07-22

Similar Documents

Publication Publication Date Title
MX2012007671A (es) Agente terapeutico (y-39983) para la disfuncion endotelial de la cornea.
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
MX2007007458A (es) Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
AU2011201462B2 (en) Method of Administering Pirfenidone Therapy
MX2011008389A (es) Sal de tipo tosilato de un derivado de 5-pirazolil-2-piridona, util en el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc).
IL219683A0 (en) Ppocess for preparing methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound
NZ599932A (en) Imidazopyridine derivatives as jak inhibitors
WO2009134866A3 (en) Cell membrane engineering
WO2012005500A3 (ko) 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물
MX2011012264A (es) Derivados spiro[2.4]heptano puenteados como agonistas del receptor de lipoxina a(alx) y/o de formil peptido tipo 2 (fprl2).
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
WO2012020412A3 (en) Fibrin based scaffold, preparation and use thereof
WO2011025167A3 (ko) 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용 가능한 염을 포함하는 암 예방 또는 치료용 약학 조성물
JP2013515676A5 (enExample)
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
IL209270A (en) Compounds containing tricyclic nitrogen and their use as antibacterial
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
MY183153A (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl) -3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl) urea hydrochloride
MX2014005400A (es) Metodos para tratar hiperucemia en pacientes con gota utilizando halofenato o acido halofenico y un segundo agente de reduccion de urato.
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
PH12014502282A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SENJU PHARMACEUTICAL CO., LTD.

FG Grant or registration